Breaking News Instant updates and real-time market news.

ARNC

Arconic

$21.45

-0.45 (-2.05%)

, APO

Apollo Global

$29.47

-0.02 (-0.07%)

19:34
10/22/18
10/22
19:34
10/22/18
19:34

Arconic to consider $11B offer from Apollo Global, Reuters reports

ARNC

Arconic

$21.45

-0.45 (-2.05%)

APO

Apollo Global

$29.47

-0.02 (-0.07%)

  • 30

    Oct

  • 31

    Oct

ARNC Arconic
$21.45

-0.45 (-2.05%)

10/10/18
MSCO
10/10/18
NO CHANGE
Target $22
MSCO
Equal Weight
Morgan Stanley says Arconic could rise to $28, or fall to $17, pending review
With Arconic expected to host an investor event in November where management is expected to share the results of their strategic review, Morgan Stanley analyst Rajeev Lalwani lays out three potential scenarios and the associated move in the stock that he sees in each theoretical case. In Scenario 1, which he views as most probable, Arconic will announce significant asset sales as it continues its shift toward becoming a pure-play A&D company. In such a scenario, Lalwani sees the stock trading at about $22 per share. In Scenario 2, the company announces a full buyout and he sees the stock moving up to about $28 per share. Lalwani puts the odds of this scenario at 30%. In Scenario 3, the company announces limited strategic activity beyond those noted to-date and in such a case Lalwani sees the stock falling to $17 per share to re-test its early 2018 lows. Ahead of the potential catalyst of the investor day and end of the review, Lalwani keeps an Equal Weight rating and $22 price target on Arconic.
09/17/18
09/17/18
DOWNGRADE

Neutral
Arconic downgraded to Neutral on valuation at Longbow
As previously reported, Longbow downgraded Arconic to Neutral from Buy. Analyst Chris Olin cites valuation, limited upside to EP&S Segment margins and recent checks that appear evenly balanced for his change in view.
09/17/18
LBOW
09/17/18
DOWNGRADE
LBOW
Neutral
Arconic downgraded to Neutral from Buy at Longbow
08/22/18
ARGS
08/22/18
NO CHANGE
ARGS
Hold
Argus looking for upgrade opportunity for Arconic
Argus analyst John Eade kept his Hold rating on Arconic but noted that he is looking to get more constructive on the company, stating that while the stock has outperformed the market over the past quarter, the performance over the past year has been much worse. Eade believes that the new management's key challenge is the rise in the input costs, but notes that he would consider returning the stock to the Buy list when margins show some signs of stabilizing.
APO Apollo Global
$29.47

-0.02 (-0.07%)

10/01/18
GSCO
10/01/18
UPGRADE
Target $45
GSCO
Conviction Buy
Apollo Global upgraded to Conviction Buy from Buy at Goldman Sachs
Goldman Sachs analyst Alexander Blostein added Apollo Global Management to his firm's Conviction List while keeping a Buy rating on the shares. Apollo at current valuation levels is now the only Alternative Manager to which the market still ascribes a negative value to future incentive earnings, Blostein tells investors in a research note. The analyst believes Apollo's investment performance is strengthening and its realization outlook is improving into 2019 and 2020. He has a $45 price target for the shares.
08/28/18
BUCK
08/28/18
NO CHANGE
BUCK
Buckingham sees RenaissanceRe, Axis Capital trading up on Aspen deal news
Buckingham analyst Amit Kumar called the multiple Apollo Global (APO) agreed to pay to acquire Aspen Insurance (AHL) "a tad underwhelming compared to other recent deals," which he attributes to Aspen's hand being forced by the fast approaching peak hurricane season and investor skepticism on its standalone future. Given the drawn out process, he sees a lower likelihood of a competing bidder emerging, Kumar tells investors, adding that he expects both RenaissanceRe (RNR) and Axis Capital (AXS) to trade up on the deal news.
08/14/18
MSCO
08/14/18
NO CHANGE
Target $42
MSCO
Overweight
Apollo Global's Q3 'setting up well,' says Morgan Stanley
Morgan Stanley analyst Michael Cyprys maintained an Overweight rating and $42 price target on Apollo Global, telling investors in a research note that Q3 is "setting up well" with key fund and balance sheet investments appreciating following a softer Q2 print. He sees Apollo's credit business scaling and new initiatives taking hold that could drive significant upside to fee-related earnings.
07/24/18
BMOC
07/24/18
NO CHANGE
Target $62
BMOC
Market Perform
LifePoint price target raised to $62 from $51 at BMO Capital
BMO Capital analyst Matt Borsch raised his price target on LifePoint (LPNT) to $62 and kept his Market Perform rating after the proposed transaction for the company to be taken private by the Apollo Global (APO) affiliate RCCH HealthCare Partners at $65 per share. The analyst says his price target reflects the acquisition price blended with some uncertainty regarding the deal, even as he views the terms of the offer as attractive to LifePoint shareholders against the"backdrop of reimbursement and volume pressures that challenge acute care hospitals".

TODAY'S FREE FLY STORIES

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.